Re-administration of abatacept for the control of articular symptoms of rheumatoid arthritis during anti-tuberculous therapy. (2017)

• Record Type: Journal Article
• Authors: Kawamoto, Hironori; Takasaki, Jin; Ishii, Satoru; Suzuki, Manabu; Morino, Eriko; Naka, Go; Iikura, Motoyasu; Izumi, Shinyu; Takeda, Yuichiro; Sugiyama, Haruhito
• Is Part Of: Respiratory medicine case reports. Volume 21(2017)
• Page Start: 147
• Page End: 150
• Publication Date: 2017
• Subjects: Tuberculosis -- Biological agent -- Abatacept -- Paradoxical reaction -- Rheumatoid arthritis; Respiratory organs -- Diseases -- Periodicals; Chest -- Diseases -- Periodicals; Respiratory Tract Diseases -- Periodicals; Respiratory System -- Periodicals; Chest -- Diseases; Respiratory organs -- Diseases; Electronic journals; Periodicals; 616.2
• DOI: 10.1016/j.rmcr.2017.04.013
• Languages: English
• ISSNs: 2213-0071

Abstract

Abstract: This case report describes the re-administration of abatacept to successfully reduce the articularsymptoms of a patient with rheumatoid arthritisduring the intensive phase of anti-tuberculous therapy. A 75-year-old man developed active pulmonary tuberculosis during the administration of abatacept for rheumatoid arthritis. The patient experienced a paradoxical reaction and exacerbation of rheumatoid arthritis that caused us to discontinue the abatacept. Later re-administration of abatacept along with anti-tuberculosis treatment led to well-controlled rheumatoid arthritis without exacerbation of the tuberculosis. This case shows that re-administration of abatacept may be much safer than TNF inhibitor to treat patients who are infected with mycobacteria during thetreatment of immunological diseases such asrheumatoid arthritiswith biological agents.